Oncoprint of alterations identified in tumor samples from patients with EGFR-mutant lung cancer pre-treatment (green) and after treatment (pink) with an EGFR TKI. The frequency is noted on the right. The type of genetic alteration (missense, inframe, truncated, amplification, deletion, fusion) is described in the legend, and the comutations present in ≥5% of cases were included in the figure. HER2 and MET amplification were included due to their relevance in acquired resistance.